Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.52 |
| ▸ | CTSK | P43235 | 2/20 | 0.50 |
| ▸ | KDM1A | O60341 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 2/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.44 |
| ▸ | RELA | Q04206 | 1/20 | 0.44 |
| ▸ | MERTK | Q12866 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 2/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | TYK2 | P29597 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL746168 | 1.00 | BTK (0.54) | BTKEPHX2CTSKKDM1AMAOB | |
| SCHEMBL1204562 | 1.00 | BTK (0.54) | BTKEPHX2CTSKKDM1AMAOB | |
| SCHEMBL6260146 | 0.93 | BTK (0.60) | BTKEPHX2CTSKKDM1AMAOB | |
| SCHEMBL6259821 | 0.93 | BTK (0.60) | BTKEPHX2CTSKKDM1AMAOB | |
| SCHEMBL6260151 | 0.93 | BTK (0.60) | BTKEPHX2CTSKKDM1AMAOB | |
| SCHEMBL3702157 | 0.92 | BTK (0.61) | BTKEPHX2CTSKKDM1AMAOB | |
| SCHEMBL3702152 | 0.92 | BTK (0.61) | BTKEPHX2CTSKKDM1AMAOB | |
| SCHEMBL1406894 | 0.92 | BTK (0.61) | BTKEPHX2CTSKKDM1AMAOB | |
| SCHEMBL10343938 | 0.92 | BTK (0.61) | BTKEPHX2CTSKKDM1AMAOB | |
| Methyl Alcohol SCHEMBL28082230 | 0.90 | BTK (0.59) | BTKEPHX2CTSKKDM1AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 869 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120004812-A | Cis-4- (5, 6-diphenyl pyrazine-2-amino) cyclohexyloxy acetic acid compound, and preparation method and application thereof | 四川轻化工大学 | 2025-05-16 | — | — | CN | claimed |
| CN-119504614-A | Cis-4- (5, 6-diphenyl pyrazine-2-amino) cyclohexyloxy acetic acid compound, and preparation method and application thereof | 四川轻化工大学 | 2025-02-25 | — | — | CN | claimed |
| CN-118955474-A | Radioisotope carbon-14 labeled bard-calide and preparation method and application thereof | 浙江爱索拓标记医药科技有限公司 | 2024-11-15 | — | — | CN | claimed |
| CN-110240608-B | Material for adsorbing hexamethyldisiloxane | 王晓景 | 2020-02-21 | — | — | CN | claimed |
| US-12624018-B1 | Inhibitors of RIPK2 and medical uses thereof | ODYSSEY THERAPEUTICS, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| US-20260125362-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | ABBVIE BIOTECHNOLOGY LTD (BM) | 2026-05-07 | — | — | US | disclosed |
| WO-2026090317-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| EP-3985001-B1 | PHARMACEUTICAL COMPOSITION FOR USE IN TREATING A CANCER | SERVIER LAB (FR) | 2026-04-29 | — | — | EP | disclosed |
| US-20260102501-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NUVATION BIO INC (US) | 2026-04-16 | — | — | US | disclosed |
| US-20260092069-A1 | SUBSTITUTED INDAZOLES AS IRAK4 INHIBITORS | ASTRAZENECA AB (SE) | 2026-04-02 | — | — | US | disclosed |
| US-20260078131-A1 | PYRROLO-PYRIDAZINE INHIBITORS OF JAK2 | AJAX THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| EP-4709486-A1 | HETEROARYL COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK4 | Celgene Corporation (US) | 2026-03-18 | — | — | EP | disclosed |
| US-5691323-A | BENZIMIDAZOL-2-ONES | MERCK & CO., INC. (US) | 1997-11-25 | — | — | US | disclosed |
| EP-0644872-B1 | ORNITHINE DECARBOXYLASE INHIBITING CYCLIC AMINOOXY COMPOUNDS | CIBA GEIGY AG (CH) | 1997-03-19 | — | — | EP | disclosed |
| US-5574044-A | BENZIMIDAZOL-2-ONE COMPOUNDS FOR TREATMENT OF MYOPIA | MERCK & CO., INC. (US) | 1996-11-12 | — | — | US | disclosed |
| US-5516806-A | ANTITUMOR | CIBA-GEIGY CORPORATION (US) | 1996-05-14 | — | — | US | disclosed |
| WO-1996013262-A1 | MUSCARINE ANTAGONISTS | MERCK & CO., INC. (US) | 1996-05-09 | — | — | WO | disclosed |
| WO-1996002553-A2 | AMINO PURINE-β-D-RIBOFURANURONAMIDE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1996-02-01 | — | — | WO | disclosed |
| EP-0644872-A1 | ORNITHINE DECARBOXYLASE INHIBITING CYCLIC AMINOOXY COMPOUNDS. | CIBA GEIGY AG (CH) | 1995-03-29 | — | — | EP | disclosed |
| WO-1994024093-A1 | ORNITHINE DECARBOXYLASE INHIBITING CYCLIC AMINOOXY COMPOUNDS | CIBA-GEIGY AG (CH) | 1994-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078131-A1 | PYRROLO-PYRIDAZINE INHIBITORS OF JAK2 | JAK2, JAK1, JAK3 | BTK 38/4885EPHX2 2048/4885CTSK 3682/4885 |
| US-20260092069-A1 | SUBSTITUTED INDAZOLES AS IRAK4 INHIBITORS | IRAK3, IRAK4, IRAK2 | BTK 18/4885EPHX2 3333/4885CTSK 3202/4885 |
| US-20260102501-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NR5A1, NR5A2, NR3C1 | BTK 4673/4885EPHX2 4172/4885CTSK 4313/4885 |
| US-12624018-B1 | Inhibitors of RIPK2 and medical uses thereof | RIPK2, RIPK1, RIPK4 | BTK 778/4885EPHX2 4317/4885CTSK 689/4885 |
| US-20260125362-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | PARP14, PARP16, PARP11 | BTK 1954/4885EPHX2 4496/4885CTSK 2301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.